A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
(Q34617756)
scientific article
scientific article
Language:
Current Data About
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma